Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 86,012 Shares

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 86,012 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $2.80, for a total value of $240,833.60. Following the completion of the sale, the chief operating officer owned 62,586 shares in the company, valued at approximately $175,240.80. This represents a 57.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The shares were sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Up 2.1%

Shares of NASDAQ EQ opened at $2.90 on Friday. The business’s 50 day moving average price is $2.11 and its 200 day moving average price is $1.64. The firm has a market cap of $183.36 million, a P/E ratio of -9.06 and a beta of 1.67. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $3.10.

Equillium (NASDAQ:EQ) last issued its earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). As a group, research analysts expect that Equillium, Inc. will post -0.24 earnings per share for the current year.

Key Equillium News

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Wall Street Analyst Weigh In

Several research firms have commented on EQ. Raymond James Financial restated a “strong-buy” rating and issued a $7.00 price objective on shares of Equillium in a research report on Thursday. Cantor Fitzgerald began coverage on Equillium in a research report on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price objective on the stock. Zacks Research upgraded Equillium to a “hold” rating in a research report on Thursday, February 26th. Stifel Nicolaus set a $5.00 price objective on Equillium in a research report on Thursday. Finally, Leerink Partners upgraded Equillium from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $1.00 to $6.00 in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its stake in shares of Equillium by 10.8% during the 1st quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock worth $12,957,000 after buying an additional 632,359 shares during the period. Eversept Partners LP acquired a new position in shares of Equillium during the 1st quarter worth approximately $2,998,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Equillium during the 1st quarter worth approximately $100,000. Affinity Asset Advisors LLC acquired a new position in shares of Equillium during the 1st quarter worth approximately $2,453,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Equillium during the 1st quarter worth approximately $31,000. 27.05% of the stock is owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.